Plasma membrane calcium ATPase (PMCA4): A housekeeper for RT-PCR relative quantification of polytopic membrane proteins by Calcagno, Anna Maria et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Molecular Biology
Open Access Research article
Plasma membrane calcium ATPase (PMCA4): A housekeeper for 
RT-PCR relative quantification of polytopic membrane proteins
Anna Maria Calcagno, Katherine J Chewning, Chung-Pu Wu and 
Suresh V Ambudkar*
Address: Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892–42546, USA
Email: Anna Maria Calcagno - calcagnoa@mail.nih.gov; Katherine J Chewning - chewningk@mail.nih.gov; Chung-
Pu Wu - wuchung@mail.nih.gov; Suresh V Ambudkar* - ambudkar@helix.nih.gov
* Corresponding author    
Abstract
Background: Although relative quantification of real-time RT-PCR data can provide valuable
information, one limitation remains the selection of an appropriate reference gene. No one gene
has emerged as a universal reference gene and much debate surrounds some of the more
commonly used reference genes, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
At this time, no gene encoding for a plasma membrane protein serves as a reference gene, and
relative quantification of plasma membrane proteins is performed with genes encoding soluble
proteins, which differ greatly in quantity and in targeting and trafficking from plasma membrane
proteins. In this work, our aim was to identify a housekeeping gene, ideally one that codes for a
plasma membrane protein, whose expression remains the same regardless of drug treatment and
across a wide range of tissues to be used for relative quantification of real-time RT-PCR data for
ATP binding cassette (ABC) plasma membrane transporters.
Results: In studies evaluating the expression levels of two commonly used reference genes coding
for soluble proteins and two genes coding for membrane proteins, one plasma membrane protein,
plasma membrane calcium-ATPase 4 (PMCA4), was comparable to the two reference genes already
in use. In addition, PMCA4 expression shows little variation across eight drug-treated cell lines and
was found to be superior to GAPDH and HPRT1, commonly used reference genes. Finally, we
show PMCA4 used as a reference gene for normalizing ABC transporter expression in a drug-
resistant lung carcinoma cell line.
Conclusion: We have found that PMCA4 is a good housekeeping gene for normalization of gene
expression for polytopic membrane proteins including transporters and receptors.
Background
Relative quantification for real-time RT-PCR requires the
use of a reference gene for normalization [1]. An "ideal"
reference gene should be expressed at similar levels in dif-
ferent cell types and under various treatment conditions.
Many commonly used reference genes or "housekeeping"
genes do not always possess these two necessary
attributes. Several commonly used housekeeping genes
were originally used as references for more qualitative
assays such as Northern blots and conventional RT-PCR,
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and their use in quantitative RT-PCR was not originally re-
evaluated[2]. Therefore, the selection of the appropriate
reference gene for performing relative quantification has
been a topic of much discussion and evaluation [1,3,4].
This becomes more critical when examining the mRNA
expression of membrane proteins, since many of the fre-
quently used reference genes are soluble proteins, which
differ significantly in total amount and in targeting and
trafficking from membrane proteins.
Membrane proteins are a major component of the human
genome, as they comprise nearly 30% of the total human
genome [5]. These proteins are also involved in approxi-
mately 85% of cell signalling pathways. The biogenesis of
membrane proteins and cytosolic proteins varies greatly.
At transcription, specific mRNA-binding proteins are
added to nascent mRNA to ensure RNA integrity and to
oversee RNA export from the nucleus, subcellular localiza-
tion, translation and stability [6]. Membrane localization
of mRNA has been reported in membrane proteins, and
this localization may facilitate cotranslational import of
some membrane transporters as is seen in Atm1, a yeast
ABC transporter of the inner mitochondrial membrane,
and Ist2, a yeast plasma membrane putative ion channel
[7]. Investigators have also shown that mRNAs that
encode for secreted or membrane proteins are preferen-
tially found in membrane-bound polysomes [8]. The
translation of secretory, integral membrane proteins as
well as that of luminal and membrane proteins of the
endoplasmic reticulum (ER) take place on membrane-
bound ribosomes of the ER [9], whereas the synthesis of
cytosolic proteins occurs on the ribosomes within the
cytoplasm. Polytopic membrane proteins have multiple
membrane spanning domains, and they are believed to
cotranslationally incorporate into the membrane of the
ER with the assistance of the translocon [10].
An important superfamily of membrane proteins is the
ATP-binding cassette (ABC) transporter family. Several
ABC transporters are linked to disease conditions in
humans including cystic fibrosis, Stargardt disease,
Dubin-Johnson syndrome, Pseudoxanthoma elasticum
and adrenoleukodystrophy [11]. In addition, the overex-
pression of ABC transporters is the predominant cause of
multidrug resistance in cancer [12], and understanding
the triggers for overexpression of these proteins upon
exposure to various drug regimens would help researchers
find ways to circumvent multidrug resistance. Therefore, a
reliable reference gene that does not change following
drug treatment is vital for the relative quantification of
ABC transporter gene expression. In this work, our goal
was to identify a housekeeping gene, ideally one that
codes for a plasma membrane protein, whose expression
remains the same regardless of drug treatment and across
a wide range of tissues for normalization of real-time RT-
PCR data for ABC transporters.
We hypothesized that plasma membrane proteins could
function as reference genes and that a plasma membrane
reference gene would be most appropriate for relative
quantification of membrane proteins consisting of 4–12
membrane spanning helices otherwise known as poly-
topic membrane proteins. As mentioned previously,
membrane protein biogenesis, in particular for polytopic
membrane proteins, involves several steps that are specific
to membrane proteins; therefore, a reference gene encod-
ing for a protein which undergoes similar process of bio-
genesis would be best to use as a reference measurement
for gene expression. First of all, to evaluate this hypothe-
sis, two commonly used soluble protein reference genes,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and hypoxanthine phosphoribosyl transferase 1
(HPRT1), and two commonly expressed plasma mem-
brane proteins, plasma membrane calcium-ATPase 4
(PMCA4) and the alpha subunit of the Na+ /K+-ATPase
(ATP1A1), were evaluated using real-time RT-PCR with a
variety of human tissue RNA samples. PMCA4 and
ATP1A1 were chosen because both are ubiquitously
expressed polytopic plasma membrane proteins. We
determined that the consistency of PMCA4's expression
profile was comparable to that of the commonly used ref-
erence genes across a panel of tissues. We then compared
these four genes in eight drug-treated cell lines, and
PMCA4 was found to be superior to GAPDH and HPRT1.
Finally, we used PMCA4 to normalize ABC transporter
expression from real-time RT-PCR for drug-resistant lung
carcinoma cells.
Results and Discussion
PMCA4 shows comparable expression to GAPDH and 
HPRT1 in various tissues
To determine the optimal concentration of total RNA to
use within our studies, the efficiency of the RT-PCR reac-
tion was evaluated over a concentration range. The stand-
ard curve for two primers for the detection of HPRT1 and
PMCA4 indicates that the efficiency is nearly 2 (Fig. 1).
Two hundred nanograms of total RNA was found to be
within the linear range of the reaction, and this quantity
was used to evaluate the primers for this and all subse-
quent studies comparing the four genes.
To evaluate the use of ATP1A1 or PMCA4 as reference
genes, their expression patterns for a variety of human tis-
sue RNA samples were compared to those of two com-
monly used reference genes, GAPDH and HPRT1. The
average crossing point values determined by real-time RT-
PCR for the 4 housekeeping genes across different tissue
samples with standard deviation are shown in Fig. 2. The
selected tissue types are known to express ABC transport-BMC Molecular Biology 2006, 7:29 http://www.biomedcentral.com/1471-2199/7/29
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ers at moderate to high levels. GAPDH and HPRT1
showed the least amount of variation for the panel of tis-
sues tested (Mean = 22.24 and variance = 1.26; Mean =
24.75 and variance = 1.64, respectively). However, similar
to GAPDH and HPRT1, PMCA4, which encodes a plasma
membrane calcium pump that removes bivalent calcium
ions from cells against very large concentration gradients
[13-16], is consistently expressed in this varying panel of
tissues (Mean = 21.17 and variance = 1.87). ATP1A1, the
alpha subunit of the plasma membrane Na+ /K+ ATPase
[17], shows a greater variance in expression compared to
either PMCA4 or the commonly used reference genes
(Mean = 20.84 and variance = 2.09). This suggests that
unlike PMCA4, ATP1A1 is not the best choice for tissue
samples as a reference gene. Further statistical analysis
using a one-sided Fisher variance-ratio, comparing the
variance for the PMCA4 samples to the variance for each
other gene samples separately, indicates that there is no
statistically significant difference (p > 0.05) between
PMCA4 expression and that of the other genes (ATP1A1 p
= 0.383; GAPDH p = 0.187; and HPRT1 p = 0.356). The
variances for the ATP1A1 samples were also compared to
the variances for the GAPDH and HPRT1 samples; the p
values were 0.118 and 0.252, respectively. Additional
studies with cell culture lines from other tissue types gen-
erated similar results (Table 1). The F-test for the cell cul-
ture lines did indicate that the variance of the ATP1A1
expression profile is statistically different than that of
PMCA4 (p = 0.041), whereas there is no statistically signif-
icant difference between the variances of the PMCA4 and
the GAPDH samples (p = 0.093) or the variances of the
PMCA4 and the HPRT1 samples (p = 0.074). There was
also a statistically significant difference between the vari-
ance of ATP1A1 and those of GAPDH and HPRT1 (both p
values = 0.001). This suggests that PMCA4 is comparable
to two established reference genes, GAPDH and HPRT1,
while ATP1A1 is not.
PMCA4 expression is unchanged under a variety of 
treatment conditions
Reference genes must be expressed at similar levels in dif-
ferent cell types and more importantly must remain con-
sistent under various treatment conditions. Our previous
results address tissue expression of PMCA4. In an attempt
to further examine the utility of PMCA4 as a reference
gene; its expression was evaluated in 8 drug-treated cell
lines. RNA was isolated from four drug-treated sublines
and from the drug-sensitive parental cells, MCF-7 and KB-
3-1. The MCF-7 (human breast adenocarcinoma) sublines
were the following: MCF-7/ADR [18], MCF-7/VP16 [19],
MCF-7FL-1000 [20], and MCF-7-ADRVP [21]. The KB-3-1
(human cervical squamous cell carcinoma) sublines were
selected with either doxorubicin (KB-A1), vinblastine
(KB-V1) or colchicine (KB-C1 and KB-8.5-11) [22]. These
drug-selected cell lines are known to overexpress ABC
transporters at the mRNA level. We also re-evaluated ABC
transporter expression levels within these lines using RT-
PCR to confirm that overexpression was present (data not
shown). The average crossing point values are given for
the different cell lines in Fig. 3. Interestingly, in this anal-
ysis, GAPDH, a commonly used reference gene, per-
formed poorly under these conditions (Mean = 17.24 and
variance = 1.21), and PMCA4 expression was the most
consistent across the various high dose drug treatments
(Mean = 21.4 and variance = 0.29). HPRT1 showed
slightly more variation than PMCA4 (Mean = 20.77 and
variance = 0.41). Again, the results for ATP1A1 (Mean =
19.49 and variance = 0.55) show that the variance is
nearly two-fold larger than that for PMCA4. This taken
together with the results from the tissue and cell line
expression studies suggests that ATP1A1 is not suitable as
a reference gene.
PMCA4, on the other hand, was found to be superior to
all other reference genes tested in this study. An F-test was
used to individually compare the variance of the PMCA4
samples to the variance of the samples for the other genes.
The variances for ATP1A1 and GAPDH, p = 0.027 and
0.00001, respectively, were statistically different than the
variance for PMCA4. No statistical difference was found
between PMCA4 and HPRT1, p = 0.146. From these
results, we first identified a reference gene which was fore-
most, a membrane protein and which would also be con-
sistent for all cell lines examined, regardless of drug
selection conditions. PMCA4 was chosen as the reference
Standard curve to evaluate efficiency of RT-PCR reaction Figure 1
Standard curve to evaluate efficiency of RT-PCR 
reaction. The HPRT1 (blue circle) and PMCA4 (red dia-
mond) primers were evaluated over a range of total RNA 
concentrations (30 ng-300 ng total RNA). The average cross-
ing point values are given for the n = 4, and the error bars 
represent ± SD.
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gene for our subsequent work because of the convincing
data from these studies. To our knowledge, this is the first
report of the use of a gene encoding a membrane protein
for normalization of real time RT-PCR data for polytopic
membrane transport proteins.
PMCA4 is a good reference gene for polytopic plasma 
membrane proteins
We have shown that PMCA4 expression is consistent and
that it should be used as a reference or housekeeping gene
for membrane proteins. To demonstrate the use of
PMCA4 for normalizing the ABC transporter expression
profile for multidrug resistant cells, we evaluated parental
COR-L23P and drug-resistant COR-L23R cells. COR-L23R
was the only doxorubicin-resistant cell line reported to
overexpress the ABC transporter, ABCC1, by step-wise
selection using high doses of doxorubicin. Further charac-
terization of multidrug resistance-linked ABC transporter
gene expression has not been reported to date for the
COR-L23R cells. Crossing point values for each trans-
porter were normalized to the respective crossing point
values for PMCA4. Data are presented as a fold change in
gene expression for the drug-resistant cell line compared
to the parental cells using the delta delta Ct method. Sur-
prisingly, our results show that only this ABC transporter
is highly overexpressed in the resistant cells. COR-L23R
overexpresses ABCC1 (> 90-fold) with doxorubicin-selec-
tion compared to parental COR-L23P cells (Fig. 4), and
no differences were found between COR-L23P and COR-
L23R expression of PMCA4 (Cp = 21) at 300 ng of total
RNA per reaction. However, if GAPDH was used as the ref-
erence gene, this fold change would be greatly inflated,
since the crossing point values between COR-L23P (Cp =
18) and COR-L23R (Cp = 20) vary by 2 crossing point val-
ues. Alternatively, the mean expression value for HPRT1
for the COR-L23P cells was 19.8 while that of the COR-
L23R cells was 20.1. Although these differences in Cp val-
ues appear to be minimal, the calculated fold change
would be highly amplified when either GAPDH or HPRT1
was used with the delta-delta Ct method (Table 2).
No other ABC transporter in our panel (consisting of the
12 ABC transporters linked to multidrug resistance) was
overexpressed, and only the transporter which was previ-
ously reported remained the ABC transporter conferring
resistance as seen by Western blotting (Fig. 4C and 4D).
ABCC1 was not detectable in the parental COR-L23P cells,
as seen in this Western Blot. Calcein-AM efflux assays
using MK-571, the typical ABCC1 inhibitor, further veri-
fied that COR-L23R cells overexpress functional ABCC1
(Fig. 4E). These results are consistent with previous
reports on the drug resistance profiles of these cells [23].
In this work, we identified a consistent housekeeping
gene, PMCA4, for plasma membrane proteins which was
comparable to other established reference genes when
examined in a diverse panel of tissues and cell lines. Our
work investigated the effects of drug treatment and tissue
type on the selection of a housekeeping gene; additional
work evaluating other conditions is currently under way.
PMCA4 was also found to be superior to these reference
genes, since it showed less variation regardless of drug
treatment for the KB-3-1 and MCF-7 cells. We also thor-
oughly characterized the ABC transporter gene expression
profile for a multi-step doxorubicin-selected cell line
using PMCA4 as the reference gene. Overexpression of
ABCC1 was verified in the COR-L23R cells at both the
mRNA and protein levels. Although we have found that
PMCA4 works quite well for the described conditions, as
for all known housekeeping genes, there are conditions
where alternative housekeeping genes may work best. For
PMCA4, other investigators reported that increased Pi lev-
els in cattle resulted in increased PMCA4 levels; neuronal
development was also linked to increased PMCA4 levels
[24,25]. PMCA4 appears to be a suitable housekeeping
gene for normalization of gene expression for polytopic
Table 1: Comparison of Housekeeping Gene Expression in Various Cell Linesa
Cell line Housekeeping Genes
ATP1A1 b GAPDH HPRT1 PMCA4
Human Salivary Gland cells 19.62 ± 0.38 16.96 ± 0.11 21.33 ± 0.21 20.61 ± 0.14
HCT-116 (colorectal carcinoma) 20.4 ± 0.67 17.33 ± 0.4 21.71 ± 0.31 21.7 ± 0.36
KB-3-1 (Cervical squamous cell carcinoma) 20.57 ± 0.36 17.73 ± 0.07 20.49 ± 0.57 22.13 ± 0.1
SNB-75 (Glioblastoma) 19.77 ± 0.27 17.49 ± 0.15 21.9 ± 0.2 19.77 ± 0.17
SF-295 (Glioblastoma) 20.62 ± 0.34 17.01 ± 0.43 21.48 ± 0.28 21.61 ± 0.13
MCF-7 (breast adenocarcinoma) 18.49 ± 0.28 17.1 ± 0.33 20.69 ± 0.13 21.39 ± 0.24
UACC-62 (melanoma) 18.66 ± 0.8 16.31 ± 0.5 21.22 ± 0.25 20.58 ± 0.3
COR-L23P (lung carcinoma) 18.14 ± 0.34 18.12 ± 0.24 20.54 ± 0.21 21.03 ± 0.17
aThe LightCycler RNA Master SYBR Green Kit and LightCycler 480 were used in these RT-PCR studies. The average crossing point values are 
given for the different cell lines ± SD (n = 4 for all samples).
bF-test comparing all values for PMCA4 and ATP1A1 indicates that there is a statistically significant difference (p = 0.041). No statistically significant 
difference is seen between PMCA4 and GAPDH (p = 0.093) or PMCA4 and HPRT1 (p = 0.074)BMC Molecular Biology 2006, 7:29 http://www.biomedcentral.com/1471-2199/7/29
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membrane proteins including transporters, ATPases and
receptors.
Methods
Chemicals and other reagents
Acetoxy-methyl ester of calcein (calcein-AM) was pur-
chased from Molecular Probes (Eugene, OR). Doxoru-
bicin was purchased from Calbiochem (San Diego, CA).
RT-PCR reagents were purchased from Roche Applied Sci-
ences (Indianapolis, IN). RNA from various tissue types
examined in Fig. 2 was purchased from Clontech (Moun-
tain View, CA).
Cell Lines
The human large-cell lung tumor line COR-L23P and its
doxorubicin-selected MRP1-overexpressing multidrug-
Quantification of commonly expressed genes encoding soluble or membrane proteins in various human tissue samples using  real time RT-PCR Figure 2
Quantification of commonly expressed genes encoding soluble or membrane proteins in various human tissue 
samples using real time RT-PCR. The expression levels of two polytopic membrane protein genes (panel A and B) and 
two soluble protein genes (panel C and D) in eight human tissue samples known to express ABC transporters were evaluated 
using RT-PCR. A) ATP1A1; B) PMCA4; C) GAPDH; and D) HPRT1. The error bars represent standard deviation (n = 4).
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Comparison of reference gene expression in drug-resistant cell lines Figure 3
Comparison of reference gene expression in drug-resistant cell lines. The two parental cell lines, MCF-7 and KB-3-1, 
and several of their drug-resistant subclones were evaluated using RT-PCR. The drug-resistant MCF-7 cell lines were as fol-
lows: MCF-7/ADR (doxorubicin-treated)[18]; MCF-7FL-1000 (flavopiridol-treated)[20]; MCF-7/VP16 (etoposide-treated) [19]; 
and MCF-7-ADRVP (adriamycin- and verapamil-treated)[21]. The KB cell lines were KB-A1 (doxorubicin-treated); KB-V1 (vin-
blastine-selected) and KB-C1 and KB-8.5-11 (colchicine-selected)[22]. A) ATP1A1; B) PMCA4; C) GAPDH; and D) HPRT1. 
The error bars represent standard deviation (n = 4).
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Evaluation of selected ABC transporter expression in lung carcinoma COR-L23 (parental and resistant) cell lines Figure 4
Evaluation of selected ABC transporter expression in lung carcinoma COR-L23 (parental and resistant) cell 
lines. A) The fold change in expression in COR-L23R cells compared to the parental cell line is depicted for the gene expres-
sion of ABC transporters. Two individual determinations of crossing point values are given. B) Western blotting with MRPr1 
antibody (1:1000) shows that only COR-L23R cell lysates express ABCC1[27]. Lane 1, 20 μg of COR-L23P; lane 2, 10 μg of 
COR-L23R; and lane 3, 20 μg of COR-L23R. C) C219 (1:1000) was used to detect ABCB1[28]. Lane 1, COR-L23P (100,000 
cells); lane 2, COR-L23R (100,000 cells); and lane 3, positive control, KB-A1 (100,000 cells). D) ABCG2 was detected with 
BXP-21 (1:1000)[29]. Lane 1, COR-L23P (100,000 cells); lane 2, COR-L23R (100,000 cells); and lane 3, positive control, MCF-
7-FL1000 (100,000 cells). E) Functional ABCC1 is expressed in COR-L23R cells as determined by calcein-AM efflux assays. 
Brown solid line histogram, COR-L23P; blue solid line histogram, COR-L23P with 20 μM MK-571; red solid line histogram, 
COR-L23R control; and green solid line histogram, COR-L23R with 20 μM MK-571. The results from a typical experiment are 
shown in the panel. Similar results were obtained on two additional experiments.
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resistant variant COR-L23R were a generous gift from
Margery A. Barrand (Department of Pharmacology, Uni-
versity of Cambridge, Cambridge, UK) [23]. Both COR-
L23P and COR-L23R cells were cultured in RPMI 1640
medium with 10% (v/v) fetal calf serum supplemented
with 100 units of penicillin/streptomycin/ml (Invitrogen)
at 37°C in 5% CO2 humidified air. The COR-L23R cells
were also maintained in the presence of 0.2 μg/ml doxo-
rubicin.
The cervical epidermal carcinoma cell line KB-3-1 and its
drug resistant subline, KB-A1, were generous gifts of
Michael M. Gottesman (Laboratory of Cell Biology,
National Cancer Institute, NIH, Bethesda, MD) [22], and
the MCF-7 breast cancer cell line and the subline MCF-7/
ADR were a generous gift of Kapil Mehta (MD Anderson
Cancer Center, Houston, TX) [18]. These cell lines were
cultured in DMEM with 10% (v/v) fetal calf serum supple-
mented with 2 mM glutamine and 100 units of penicillin/
streptomycin/ml (Invitrogen) at 37°C in 5% CO2 humid-
ified air. The drug resistant subline KB-A1 was kept under
constant selection in 1 μg/ml doxorubicin while 0.5 μg/
ml doxorubicin was added to the MCF-7/ADR cells every
other passage.
RNA Isolation
RNA was isolated from cells grown in 6-well plates to
characterize reference gene expression in all cell lines and
to characterize ABC transporter expression in the parental
COR-L23P and drug-resistant COR-L23R cell lines. In
these studies, 6-well plates were seeded at 200,000 cells
per well for each cell type, and RNA was isolated following
72 hr of growth. Drug-resistant cell lines were plated with
the appropriate concentration of drug during the 72 hr
period. The medium and any detached cells were removed
from the wells. RNA isolation was performed on the cells
that remained attached using the Qiagen RNeasy kit
(Valencia, CA) as per the manufacturer's protocol with a
15 minute on-column DNAse incubation step. RNA sam-
ples were isolated in triplicate. The pure RNA was quanti-
fied using the Nanodrop ND-1000 Spectrophotometer
(Wilmington, DE). The integrity of the RNA was verified
using the Agilent 2100 Bioanalyzer (Palo Alto, CA) with
the Eukaryote Total RNA Nano assay. The RNA samples
were stored at -80°C until needed.
Quantitative RT-PCR
Real-time quantitative RT-PCR was used to measure the
mRNA expression levels of the four reference gene candi-
dates and the selected ABC transporters. The LightCycler
RNA Master SYBR Green Kit and LightCycler II or LightCy-
cler 480 instrument (Roche Biochemicals, Indianapolis,
IN) were utilized in these studies. Primers for these genes
were designed using the Roche Probe Design 2 software.
All primer sets were tested prior to use in this work to
ensure that only a single product of the correct size was
amplified for all primer sets. The primer set for PMCA4
was designed to a region which is common to each of the
splice variants and does not differentiate between them.
(The list of primers is given in Table 3).
Two hundred nanograms of total RNA with 250 nM prim-
ers were used to evaluate the primers for the studies com-
paring the four reference genes. The LightCycler RNA
Master SYBR Green Kit and LightCycler 480 instrument
(Roche Biochemicals, Indianapolis, IN) were utilized in
these studies to determine which of the four reference
genes would be the most consistent across tissue types and
treatment conditions. The average crossing point values
for 4 housekeeping genes across different tissue samples
with standard deviation were determined, and the RT-PCR
conditions were as described in the manufacturer's proto-
col for the RNA Master SYBR Green kit. Negative controls
consisting of no-template (water) reaction mixtures were
run with all reactions.
The RT-PCR reaction for ABC transporters was performed
on 300 ng total RNA with 250 nM specific primers under
the following conditions in the LightCycler II: reverse
transcription (20 min at 61°C), one cycle of denaturation
at 95°C for 30 seconds, and PCR reaction of 45 cycles
with denaturation (15s at 95°C), annealing (12s at
58°C), and elongation (30s at 72°C with a single fluores-
cence measurement). The PCR reaction was followed by a
melting curve program (65–95°C with a heating rate of
0.1°C per second and a continuous fluorescence measure-
ment) and then a cooling program at 40°C. Negative con-
trols consisting of no-template (water) reaction mixtures
were run with all reactions. PCR products were also run on
agarose gels to confirm the formation of a single product
at the desired size. Crossing points for each transcript were
Table 2: Evaluation of ABCC1 Fold Change Using Different Housekeeping Genesa
Gene Used for Relative Quantification Fold Change of ABCC1 in COR-L23R cells Compared to parental COR-L23P cells
PMCA4 90.7 ± 7.1
GAPDH 407.8 ± 98.9
HPRT1 152.3 ± 58.9
aThe delta-delta Ct method was used with the various reference genes to calculate the fold change in ABCC1 for the COR-L23R cells compared to 
the parental COR-L23P cells.BMC Molecular Biology 2006, 7:29 http://www.biomedcentral.com/1471-2199/7/29
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determined using the 2nd derivative maximum analysis
with the arithmetic baseline adjustment. Crossing point
values for each transporter were normalized to the respec-
tive crossing point values for reference gene plasma mem-
brane calcium ATPase 4. Data are presented as a fold
change in gene expression for the drug resistant cell lines
compared to the parental cells using the delta delta Ct
method.
Western Blotting
For the Western blotting assays, cells were harvested and
the cell lysates were prepared from drug-resistant and
parental cells using a lysis buffer containing 10 mM Tris,
pH 8.0, 1% Triton X 100, 2 mM DTT, 1% aprotinin, 1 mM
AEBSF, and DNase. Following brief sonication and the
addition of SDS, equivalent numbers of cells were loaded
and separated by 7% NuPAGE gels. The electrophoressed
proteins from the gel were transferred to a nitrocellulose
membrane and probed with the appropriate primary anti-
bodies specific for the ABC protein of interest. Immunob-
lotting was performed using the C219 (1:2000) antibody
for ABCB1, MRPr1 (1:1000) (Alexis) for ABCC1, Anti-
BCRP (1:1000) for ABCG2, and the anti-mouse IgG-
horseradish peroxidase (HRP) conjugated (1:10000) sec-
ondary antibody. HRP-dependent luminescence was
developed using Western lighting chemiluminescence
reagent plus (PerkinElmer, Wellesley, MA). The blot was
exposed to Hyperfilm within a Hypercassette for various
times. The intensity of bands on the blot was quantitated
using a scanner and ImageQuant software (Piscataway,
NJ).
Assay of transport of fluorescent substrates by flow 
cytometry
A FACSort flow cytometer equipped with Cell Quest soft-
ware (Becton-Dickinson, Franklin Lakes, NJ) was used for
FACS analysis. Briefly, 300,000–500,000 cells were har-
vested after trypsinization by centrifugation at 500 × g and
then resuspended in IMDM supplemented with 5% Fetal
Bovine Serum. 0.25 μM calcein-AM was added to the cells
in 4 ml of IMDM in the presence or absence of a specific
inhibitor for the ABC transporter evaluated. For example,
20 μM MK571 was used to specifically inhibit ABCC1. The
cells were incubated in a water bath at 37°C in the dark
for 10 minutes for a calcein-AM efflux assay prior to being
pelleted by centrifugation at 500 × g. The cell pellet was
then resuspended in 300 μl of PBS containing 0.1 % BSA
and then analyzed immediately using the flow cytometer
as described previously [26].
Statistics
Comparisons between the expression profiles for PMCA4
and each of the other genes was performed using a one-
tailed F-test two sample for variances, with a confidence
level of 0.05.
Abbreviations
ABC, ATP binding cassette; calcein-AM, calcein acetoxy-
methyl ester; MRP, multidrug resistance protein; MK-571,
(3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl) ((3-
(dimethyl amino-3-oxo propyl)thio)methyl)thio)propa-
noic acid; PAGE, polyacrylamide gel electrophoresis; Pgp,
P-glycoprotein; GAPDH, Glyceraldehyde-3-phosphate
dehydrogenase; HPRT, Hypoxanthine phosphoribosyl
transferase 1; PMCA4, Plasma Membrane Calcium-
ATPase 4; ATP1A1, Na+ /K+-ATPase
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Table 3: List of Primers used for RT-PCR
GENE Position of primer Forward oligo sequence Reverse oligo sequence
ABCA2 238–684 CATCCCCCTGGTGCTGTTCTT GCTTGGGCCGTGCTATTGG
ABCA3 437–939 GCCCTCTTTACACTCAGTTTTCA GACGAGCAGTTGTCGTACCTAAT
ABCA4 3380–3555 TCTGGGATCTGCTCCTGAAGTATCG GGTTAAGTACAAGCCTGTGCCAAAG
ABCB1 834–1086 GCCTGGCAGCTGGAAGACAAATAC ATGGCCAAAATCACAAGGGTTAGC
ABCB11 2204–2371 CTTCCATCCGGCAACGCT CACTGAATTTCAGAATCCTCCTAACTGGG
ABCC1 1119–1670 AGTGGAACCCCTCTCTGTTTAAG CCTGATACGTCTTGGTCTTCATC
ABCC2 872–1027 AATCAGAGTCAAAGCCAAGATGCC TAGCTTCAGTAGGAATGATTTCAGGAGCAC
ABCC3 2572–2725 TCCTTTGCCAACTTTCTCTGCAACTAT CTGGATCATTGTCTGTCAGATCCGT
ABCC4 3880–4124 TGATGAGCCGTATGTTTTGC CTTCGGAACGGACTTGACAT
ABCC5 3692–3864 AGAGGTGACCTTTGAGAACGCA CTCCAGATAACTCCACCAGACGG
ABCC11 3025–3560 CCACGGCCCTGCACAACAAG GGAATTGCCAAAAGCCACGAACA
ABCG2 266–646 CCGCGACAGTTTCCAATGACCT GCCGAAGAGCTGCTGAGAACTGTA
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GAPDH 181–587 CCCTTCATTGACCTCAACTACAT ACGATACCAAAGTTGTCATGGAT
HPRT1 496–589 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT
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